Other HDAC inhibitors including abexinostat, resminostat, givinostat, panobinostat, pracinostat, vorinostat and CUDC-101 have shown encouraging anti-cancer properties at pre-clinical and clinical trials [110]. This evidence concerns the gene HDAC9 and cancer.